Introduction {#s0005}
============

Triple negative breast cancer (TNBC) is a breast cancer subtype that lacks expression of hormone receptors (ER, PR) and HER2 amplification [@bb0005], [@bb0010]. It represents 15--20% of all breast cancer cases in the United States. Gene expression profiling broadly classifies breast cancers into luminal A and B, HER2, and basal intrinsic molecular subtypes [@bb0015], [@bb0020]. Most TNBC tumors overlap with the basal intrinsic subtype, characterized by expression of basal keratins 5, 6, 14, and 17 [@bb0025], [@bb0030]. More recently, further classification of TNBC by gene expression has resulted in four major subtypes of TNBC [@bb0035], [@bb0040], including basal-like (BL) 1 and 2, mesenchymal (M), and luminal androgen-receptor (LAR). Despite the refinement of TNBC classification, it is not clear whether different subtypes of TNBC are driven by diverse signaling pathways during malignant initiation, progression or metastasis. Similarly, it is not yet clear whether patients assigned to these novel subtypes of TNBC present different therapeutic opportunities or whether each subtype has different levels of resistance to therapy, although results using small cohorts are consistent with this notion [@bb0045], [@bb0050].

Patients diagnosed with TNBC have significantly worse clinical outcomes than patients diagnosed with luminal disease [@bb0055], [@bb0060]. Furthermore, epidemiological studies in the US have reported an increased prevalence and higher mortality rate of TNBC in young African American women compared to other groups [@bb0065], [@bb0070], [@bb0075]. Targeted therapy for TNBC using EGFR [@bb0080], Src [@bb0085], and MEK [@bb0090] inhibitors have been tested in TNBC patients, but have not significantly improved the outcomes although PARP inhibitors have promising efficacy in patients whose tumors harbor BRCA mutations [@bb0095]. The current standard of care for TNBC consists of anthracycline and taxane-based chemotherapy regimens [@bb0100] in the neoadjuvant, adjuvant, and metastatic setting [@bb0105], [@bb0110]. Despite a high response rate of TNBC to chemotherapy, fewer than 30%, of those that progress to metastatic TNBC, survive 5 years after diagnosis [@bb0115], [@bb0120]. Currently the relationship between the different subtypes of TNBC and their response to treatment or their resistance to therapy is beginning to be elucidated [@bb0125], [@bb0130]. Furthermore it has been postulated that resistance to chemotherapy can occur in TNBC and other cancers because a subpopulation of cancer stem (CSC) cells are relatively resistant to chemotherapy (reviewed in [@bb0135]).

The oncogene AIB1 (AIB1/SRC3/NCOA3) is a member of the nuclear receptor coactivator family and interacts with nuclear receptors as well as a host of transcription factors, including NF-κB [@bb0140], E2F1 [@bb0145], STAT6 [@bb0150] to influence gene transcription (reviewed in [@bb0155], [@bb0160]). Clinical correlative data has shown that AIB1 expression is associated with worse outcomes in estrogen receptor (ER) positive luminal breast cancer [@bb0165] and contributes to anti-estrogen tamoxifen resistance [@bb0170], [@bb0175]. AIB1 also plays a role in the signaling and in the progression of HER2 amplified breast cancers [@bb0180], [@bb0185]. However, a role for AIB1 in TNBC is not well defined, although there is a reported association between higher mRNA levels of AIB1 and decreased overall survival of TNBC patients [@bb0190]. In the present study, we sought to determine the role of AIB1 in TNBC using established cell lines from African American women [@bb0195], [@bb0200], [@bb0205] and from a patient derived xenograft.

Results {#s0010}
=======

TNBC Cells That Survive Chemotherapy Have Reduced Protein Levels of AIB1 {#s0015}
------------------------------------------------------------------------

Chemotherapy treatment can result in the enrichment of slow-proliferating, stem-like, tumor initiating cells (TIC) that may lead to therapy resistance [@bb0210], [@bb0215], [@bb0220], [@bb0225]. We have previously reported that AIB1 is involved in the maintenance of TIC in a ductal carcinoma *in situ* (DCIS) cell line [@bb0230]. Thus, we sought to determine if cytotoxic chemotherapy could modulate the expression of AIB1 in BL1 (HCC1806) and BL2 (MDA-MB-468) TNBC lines. Single-agent, IC~50,~ treatment ([Figure 1](#f0005){ref-type="fig"}*A*) with either Doxorubicin (DXR, 90 nM), Paclitaxel (PTX, 2 nM), or 5-Fluorouracil (5FU, 4.9 μM) resulted in significant cell death and reduced cell proliferation as measured by TrypanBlue exclusion or cell trace analysis ([Figure 1](#f0005){ref-type="fig"}, *A* and *B*). Interestingly, the chemotherapy surviving population of HCC1806 and MDA-MB-468 cells had reduced protein levels of AIB1 ([Figure 1](#f0005){ref-type="fig"}*C*). We thus evaluated the protein expression of known AIB1 downstream targets such as E-cadherin, β-catenin and NF-κB that have also been reported to contribute to TNBC chemotherapy resistance ([@bb0140], [@bb0235], [@bb0240], respectively). Indeed, we observed down-regulation of AIB1 downstream targets at the protein level in the chemotherapy surviving HCC1806 cells and MDA-MB-468 ([Figure 1](#f0005){ref-type="fig"}*C* and [Supplementary Figure 1](#f0030){ref-type="graphic"}*A*). Of note is that flow cytometry analysis of AIB1 in untreated TNBC cell lines demonstrated that nearly all cells (\>97%) expressed high and homogeneous levels of AIB1 ([Supplementary Figure 1](#f0030){ref-type="graphic"}*B*). To extend these observations, we obtained a TNBC patient derived xenograft (PDX-HCI010) developed by DeRose and colleagues [@bb0245]. PDX models represent with high fidelity human tumor progression in immunocompromised mice [@bb0250]. We determined that the PDX tumor expressed AIB1 by IHC ([Figure 1](#f0005){ref-type="fig"}*D*, left). Subsequently, we established a cell line from the PDX tumor and treated this with DXR \[0.25 μM\], PTX \[0.79 μM\], or 5FU \[32.8 μM\] and also observed significant reduction of AIB1 protein levels in surviving cells under both adherent and in-suspension conditions ([Figure 1](#f0005){ref-type="fig"}*D*, right) as seen in the established TNBC cell lines.

Depletion of AIB1 From TNBC Cell Lines Selects for a Surviving Subpopulation Expressing Low Levels of AIB1 {#s0020}
----------------------------------------------------------------------------------------------------------

Our lab has previously shown that reduced expression of AIB1 affects the proliferation rate and the phenotype of MDA-MB-231 cells, a mesenchymal subtype of TNBC, *in vitro* [@bb0255]. To further investigate the functional significance of AIB1, we reduced AIB1 expression using lentiviral transduction with two distinct shRNAs (shAIB1\#1 and shAIB1\#2) and compared that to a scrambled control shRNA in cell lines representing three different subtypes of TNBC ([Supplementary Figure 1](#f0030){ref-type="graphic"}*C*). Following puromycin selection, there was a significant reduction in cell survival (25%--60%) in the AIB1 shRNA transduced cells relative to their controls across the three subtypes of TNBC cell lines ([Figure 2](#f0010){ref-type="fig"}*A*) that correlated with reduced AIB1 protein levels ([Figure 2](#f0010){ref-type="fig"}*B*). Reduced cell viability after shRNA transduction was not an off-target effect of the lentiviral infection or puromycin selection because transient knock-down with AIB1 siRNA also reduced cell numbers that correlated with reduced levels of AIB1 protein ([Supplementary Figure 1](#f0030){ref-type="graphic"}, *D*-*F*). Surviving cells after AIB1 shRNA maintained lower levels of AIB1 in serial passage (AIB1^LOW^) ([Supplementary Figure 2](#f0035){ref-type="graphic"}*A*) and further experiments were conducted on HCC1806 AIB1^LOW^ cells. The phenotype of the HCC1806 AIB1^LOW^ cells differs from control shRNA cells showing increased proliferation in reduced serum containing media but not after 10%-serum supplement ([Figure 2](#f0010){ref-type="fig"}*C* and [Supplementary Figure 2](#f0035){ref-type="graphic"}*B*). We also observed a small but significant increase in IC~50~ for both DXR and 5FU under low serum conditions in HCC1806 AIB1^LOW^ compared to shRNA control cells ([Figure 2](#f0010){ref-type="fig"}*D*). Gene expression analysis of HCC1806 AIB1^LOW^ cells showed a number of differentially regulated genes compared to control shRNA cells that are shown in [Supplementary Figure 2](#f0035){ref-type="graphic"}*C*. Taken together, the reduction in AIB1 protein levels in TNBC cell lines appears to select for a cell subpopulation with a distinct gene expression profile.

AIB1^LOW^ Cells Result From Clonal Expansion of a Subpopulation With a Distinct Genetic Profile {#s0025}
-----------------------------------------------------------------------------------------------

Cultured cell lines adapt to *in vitro* culture conditions although they maintain genetic, molecular, and phenotypic heterogeneity [@bb0260], [@bb0265] similar to intratumoral heterogeneity observed in human cancers [@bb0270]. As shown above the analysis of the parental TNBC cells for expression of the AIB1 protein by flow cytometry showed a relatively homogenous distribution of protein expression levels in HCC1806 or MDA468 cells ([Supplemental Figure 1](#f0030){ref-type="graphic"}*B*). Therefore we speculated that the parental TNBC cell lines contain subpopulations with different dependence on AIB1 for their survival and that the depletion of endogenous AIB1 would result in the selection of cells that are less dependent on the expression of AIB1. To further assess the cell population heterogeneity we performed whole exome sequence analysis on cells that survived after control shRNA or AIB1 shRNA transduction and selection (passage 5). Homozygous mutations did not show a difference between the control and AIB1 shRNA cell lines. However, heterozygous alterations revealed differences: The comparison of the two HCC1806 AIB1^low^ lines showed an indistinguishable pattern between them. A high portion of AIB1^low^ cells (20% - 50%) carry a heterozygous mutation pattern that is also present in the control shRNA transduced cells yet diluted by other populations resulting in a significantly lower abundance (\<20%) ([Figure 2](#f0010){ref-type="fig"}*E*). It is noteworthy that the higher portion of heterozygous mutations in the AIB1 depleted cell populations was evenly distributed across all chromosomes ([Supplemental Figure 2](#f0035){ref-type="graphic"}*D*). This shows that depletion of AIB1 reveals a pre-existing subpopulation in the parental line that is less dependent on AIB1 expression for their survival.

TNBC Cells With Reduced Levels of AIB1 Have Reduced Tube Forming Capacity {#s0030}
-------------------------------------------------------------------------

One property of cancer stem cells (CSC) *in vitro* is their ability to form spheres in non-adherent conditions [@bb0275]. Because we observed differences in attachment kinetics with HCC1806 AIB1^LOW^ cells relative to control shRNA cells when seeded onto uncoated culture dishes ([Supplementary Figure 3](#f0040){ref-type="graphic"}, *A*--*C*), we conjectured that AIB1^LOW^ cells might be related to a cancer stem-like population. Tumorspheres embedded in Matrigel-or in ultra-low attachment (ULA) conditions [@bb0280], showed no differences in size or count between groups in low serum (1%) growth media ([Supplementary Figures 3](#f0040){ref-type="graphic"}, D--I, top). However, we observed an increased number of tumorspheres with \>30 μm diameter HCC1806 AIB1^LOW^ cells relative to control shRNA when cultured in serum-free RPMI basal growth media ([Supplementary Figure 3](#f0040){ref-type="graphic"}, *H* and *I*, bottom). An additional property of CSC is related to tube-formation, a phenomenon related to vascular mimicry in where cancer cells form channels that connect to blood vessels for nutrients and oxygen [@bb0285]. Tube-formation assays were initially described using human umbilical vein endothelial cells (HUVEC) [@bb0290] ([Figure 3](#f0015){ref-type="fig"}*A*). We have previously reported AIB1 depleted mouse endothelial cells have reduced tube formation capacity [@bb0295]. Control shRNA HCC1806 cells also have an intrinsic tube formation capacity ([Figure 3](#f0015){ref-type="fig"}*B*) but this phenotype is significantly reduced in HCC1806 AIB1^LOW^ cells that maintain low expression of AIB1 mRNA following culture on a substrate matrix ([Figure 3](#f0015){ref-type="fig"}, *B*--*D*). Similarly, reducing AIB1 protein levels using a small molecule (MCB613) [@bb0300] also inhibited HCC1806 cell tube formation ([Supplementary Figure 3](#f0040){ref-type="graphic"} J and K). HCC1806 cells that survived DXR, PTX, or 5FU treatment with reduced levels of AIB1 protein ([Figure 1](#f0005){ref-type="fig"}*C*) have a similar decreased tube formation phenotype ([Figure 3](#f0015){ref-type="fig"}*E*). This effect is not restricted to basal like subtypes of TNBC because MDA-MB-157 AIB1^LOW^ cells, a mesenchymal subtype of TNBC, also have a reduced tube formation phenotype relative to their respective control shRNA ([Figures 3](#f0015){ref-type="fig"}, *F* and *G*). Thus, AIB1 expression is important for tube formation in a number of TNBC cell lines, as well as in chemotherapy-treated surviving cells.

Differential Gene Expression in HCC1806 AIB1^LOW^ Cells Grown on Matrigel™ {#s0035}
--------------------------------------------------------------------------

To define signaling pathways that could be involved in the impaired tube formation phenotype of HCC1806 AIB1^LOW^ cells relative to control shRNA cells, we performed microarray analysis on cells grown on Matrigel™. The top 50 differentially expressed genes (DEGs) with \>1.5-fold change and *P* \< .05 are depicted in the heatmap in [Figure 4](#f0020){ref-type="fig"}*A*. The results from gene expression analysis revealed a dynamic shift of DEGs from cell lines grown on plastic compared to cells grown on Matrigel. For instance, overall upregulated genes in AIB1^LOW^ cells from tube formation assays represented 29% (*n* = 15) compared to 84% (*n* = 38) in AIB1^LOW^ cells grown in uncoated cell culture dishes ([Figure 4](#f0020){ref-type="fig"}*A* and [Supplementary Figure 2](#f0035){ref-type="graphic"}*C*) highlighting cell differentiation states influenced by the culture conditions. However, the transcription factor SRY-Box9 (*SOX9*), a regulator of differentiation, was upregulated in (BL2) HCC1806 AIB1^LOW^ cells independent of culture conditions ([Figure 4](#f0020){ref-type="fig"}*A* and [Supplementary Figure 2](#f0035){ref-type="graphic"}*C*). Conversely, downregulated genes in AIB1^LOW^ cells harvested from tube formation assays represented 71% (*n* = 37) compared to 16% (*n* = 7) in AIB1^LOW^ cells grown in uncoated cell culture dishes ([Figure 4](#f0020){ref-type="fig"}*A* and [Supplementary Figure 2](#f0035){ref-type="graphic"}*C*). Of most relevance to the tube formation phenotype, six of the top ten down-regulated genes (*HEY2*, *PCSK5*, *CEACAM6*, *OLFM4*, *TRIM31*, and *PRR5L*) in HCC1806 AIB1^LOW^ cells are associated with integrin activity and/or cell adhesion consistent with our *in vitro* assays ([Figure 3](#f0015){ref-type="fig"}*B* and [Supplementary Figure 3](#f0040){ref-type="graphic"}*A*). Gene set enrichment analysis (GSEA) using the detectable nearly 10,000 genes revealed KRAS as well as WNT-β-Catenin related pathways to be downregulated in tube-forming HCC1806 AIB1^LOW^ cells relative to control shRNA cells ([Figure 4](#f0020){ref-type="fig"}*B*). Conversely, enrichment of MYC targets and inflammatory pathways was observed in the HCC1806 AIB1^LOW^ cells ([Figure 4](#f0020){ref-type="fig"}*C*) and examination of overlapping genes within the leading-edge showed that *CXCL10* was common to all inflammatory pathways. *TNF*, *IL1β*, and *CSF2* were common to both IL6- and TNFα-related signaling pathways ([Supplementary Figure 4](#f0045){ref-type="graphic"}*A*). We independently confirmed differential and leading-edge gene expression changes ([Supplementary Figures 4](#f0045){ref-type="graphic"}, *B* and *C*). Thus, when TNBC cells are in contact with extracellular matrix (ECM), AIB1 regulates a number of adhesion and inflammatory signaling pathways associated with tube formation and this regulation is inhibited in AIB1^LOW^ cells.

HCC1806 AIB1^LOW^ Cells Have Reduced Growth and Metastatic Capacity *In Vivo* {#s0040}
-----------------------------------------------------------------------------

To further characterize HCC1806 AIB^LOW^ cells, we examined their tumorigenicity and metastatic potential *in vivo*. Orthotopic injections of 1×10^6^ AIB1^LOW^ or control shRNA HCC1806 cells resulted in comparable tumor sizes by 3-weeks post injection ([Supplementary Figure 5](#f0050){ref-type="graphic"}, *A* and *B*). Histological analysis showed similar highly invasive and aggressive tumors with high degree of ischemic necrosis comparable in both groups ([Supplementary Figure 5](#f0050){ref-type="graphic"}*C*). HCC1806 AIB1^LOW^ tumor cells showed reduced staining for AIB1 protein by IHC compared to control shRNA tumors ([Supplementary Figure 5](#f0050){ref-type="graphic"}*C*) but stromal accumulation of collagen and glycoproteins showed no significant differences ([Supplementary Figure 5](#f0050){ref-type="graphic"}*D*). HCC1806 cells are highly aggressive and grow rapidly *in vivo*. Therefore, to compare the tumorigenicity of HCC1806 AIB1^LOW^ cells to control shRNA cells we set up limiting dilution assays (LDA) *in vivo* by injecting either 50, 500 or 5000 cells into the clear mammary fat pad of immunocompromised mice. After tumor size reached a group average of \~50 mm^2^, we performed survival surgery and monitored the mice for three additional weeks to detect metastasis ([Figure 5](#f0025){ref-type="fig"}*A*). Target tumor size in LDA5000 or LDA500 groups was reached by 3.7 and 4.7 weeks, respectively, with little tumor size variability ([Figure 5](#f0025){ref-type="fig"}*B*, left and middle panels). On the other hand, greater tumor size variability was observed in the LDA50 groups which took 6-weeks to reach the target size. Most of the LDA50-AIB1^LOW^ xenografts were significantly smaller than the control shRNA xenografts ([Figure 5](#f0025){ref-type="fig"}*B*, right panel). We also detected negative to low reactivity for AIB1 protein in all LDA50-AIB1^LOW^ xenografts relative to controls by IHC ([Figure 5](#f0025){ref-type="fig"}*C*). Thus, rapid growth of the outlier, LDA50-AIB1^LOW^ \#135R, xenograft is not caused by re-expression of AIB1. The overall histology for both LDA50-AIB1^LOW^ and LDA50-control shRNA xenografts was comparable to injections using higher densities of tumor cells; although a trend showing reduced necrosis in LDA50-AIB1^LOW^ xenografts may be associated with their reduced tumorigenicity ([Supplementary Figure 5](#f0050){ref-type="graphic"}*F*). Analysis of human gene expression of the LDA50 tumors using the NanoString platform indicated that the AIB1^LOW^ xenografts showed \>1.5-fold down-regulation of several genes associated with tissue remodeling, including matrix metalloproteases (*MMP*) 2, 9 & 10, pentraxin 3 (*PTX3*), metallo-protease inhibitor *TIMP4* and cathepsin (*CTSH*) [@bb0305], genes that predict chemotherapeutic response, such as *SERPINE1* and A-kinase anchoring protein 12 (*AKAP12*) [@bb0310], as well as genes associated with inflammatory pathways, such as interleukin 11 (*IL11*) and podoplanin (*PDPN*) [@bb0315], [@bb0320], and the cellular adhesion gene Cadherin 2 (CDH2) [@bb0325]. Additionally, we found several genes involved in the blood clotting cascade and regulation of the vascular system, such as *SERPINE1*, Fibronectin (*FN1*), *FOXC2*, and *PTX3* to be downregulated in LDA50-AIB1^LOW^ xenografts relative to control xenografts ([Figure 5](#f0025){ref-type="fig"}*D*). We validated expression of *FN1* and *MMP2* by qRT-PCR ([Figure 5](#f0025){ref-type="fig"}*E*). Taken together, our results demonstrate that the reduced tumor size in LDA50 HCC1806 AIB1^LOW^ correlates with gene expression related to tumor-stromal crosstalk. Notably pulmonary metastases were found in the majority of the LDA50 control shRNA mice whereas metastases were only detected in the outlier (\#135) in the LDA-AIB1^LOW^ mice; although, these were smaller relative to the pulmonary metastases of controls by H&E and Keratin 14 or E-cadherin IHC staining ([Figure 5](#f0025){ref-type="fig"}, *F* and *G*).

Finally, we explored the relevance of the gene expression changes seen in xenografts from AIB1^LOW^ cells. We analyzed whether the combined signature of 20 differentially expressed genes (DEGs) from the PanCancer Progression NanoString array correlates with outcomes in patients following chemotherapy. For this, we used the Kaplan Meier plotter ([www.kmplot.com](http://www.kmplot.com)/){#ir0005}), an interactive website that analyses the effect of gene expression on survival [@bb0330]. We restricted our analysis to breast cancer patients that received chemotherapy (*n* = 1616) as their only mode of treatment and excluded those that were in the untreated control group or that underwent endocrine therapy. Breast cancer patients that received chemotherapy treatment and that showed the 20 gene AIB1^LOW^ expression signature in their tumors had an almost 4 years (45.3 months) shorter median relapse free survival (171.4 months) than patients whose tumors lacked the AIB1^LOW^ expression signature (216.7 months; *P* \< .005; [Supplemental Figure 6](#f0055){ref-type="graphic"}).

Figure 1**Chemotherapy downregulates AIB1 expression in TNBC cell lines.** (A) HCC1806 and MDA-MB-468 cells were treated as shown (left panel) with DXR, PTX and 5FU. Viable cells were determined by Trypan blue exclusion (*n* = 4) (right panel) (B) Total count of HCC1806 cells labeled with Cell Trace Violet dye (left) following chemotherapy treatment (*n* = 2) and percent distribution of dividing cells by doubling generations (right). (C) Representative Western blot images for AIB1, E-cadherin, β catenin, and NF-kB from chemotherapy-treated surviving HCC1806 and MDA-MB-468 cells (*n* = 2) (D) H&E and AIB1 IHC staining of HCI010 PDX tumor grafts (left) and Western blot images (right) of HCI010 PDX-derived cell lines treated as in A. Graphs are representative of three independent experiments. Technical repeats shown. Mean ± SEM. Scale bar: 200 μm. One-way ANOVA followed by Sidak\'s (A and C) or Dunnett\'s (B) multiple comparisons test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Figure 1Figure 2**Phenotype of AIB1 shRNA on BL2-HCC1806 cells *in vitro*.** (A) Cell count per field (*n* = 5) (left axis) and percent survival (right axis) of TNBC cell lines following AIB1 shRNA infection and selection relative to their respective control shRNA. (B) Representative Western images for AIB1 in cells from A. (C) Proliferation of serial passaged HCC1806 AIB1^LOW^ relative to control shRNA in 10%, 1%, 0.1% serum-supplemented RPMI 1640 growth media or serum-free basal media. (D) IC~50~ from dose response curves of 72-hours chemotherapy treated HCC1806 AIB1^LOW^ cells and control shRNA in 1% or 10% serum-supplemented culture conditions. Graphs are representative of three independent experiments. Mean ± SEM. Linear regression (slope coefficient) and Non-linear regression (least-squares) for each cell type. (E) Genomic variant analysis of HCC1806 AIB1^LOW^ relative to control shRNA (passage 5). Quantification of variant reads (16 variants on 6 chromosomes, *n* = 2) is shown as a percentage of total reads. One-way ANOVA followed by Dunnett\'s multiple comparisons test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Figure 2Figure 3**AIB1**^**LOW**^**TNBC cells have reduced tube formation phenotype.** (A) Schematic of tube formation assay on Matrigel™. (B) Representative images of 48-hour tube-formation assays showing HCC1806 AIB1^LOW^ compared to control shRNA cells and (top) and network mask (bottom) (C) Bar graphs showing average of tube network length per well (*n* = 6). (D) *AIB1* mRNA expression of cells from B. (E) Representative micrographs of 48-hours tube-formation assay of HCC1806 cells that survived chemotherapy *vs* DMSO control (F) Representative micrographs of tube-formation assays showing AIB1^LOW^ compared to control shRNA MDA-MB-157 cells at indicated time points. (G) Average tube network length measured per image (*n* = 6) of tube-formation from F. Graphs are representative of three independent experiments. Mean ± SEM. Scale bar = 1 mm. Two-tailed t-test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Figure 3Figure 4**Gene expression patterns of HCC1806 AIB1**^**LOW**^**cells with reduced tube-formation phenotype.** (A) Heatmap showing differentially expressed genes in HCC1806 AIB1^LOW^ cells relative to control shRNA from tube formation assays. Bold, overlapping genes with 2D cultures. Arrowheads, RT-qPCR validation performed. Gene enrichment plots showing (B) down-regulated and (C) up-regulated pathways in HCC1806 AIB1^LOW^ cells relative to control shRNA (*n* = 2). Gene expression fold change and NES FDR as indicated.Figure 4Figure 5**Limiting dilution HCC1806 AIB1**^**LOW**^**cells have reduced growth and metastatic capacity *in vivo*.** (A) Schematic timeline for *in vivo* limiting dilution analysis. (B) Individual tumor size of HCC1806 AIB1^LOW^ and control shRNA per LDA group (*n* = 10). (C) Representative images of H&E and IHC staining of primary tumor grafts for HCC1806 AIB1^LOW^ and control shRNA. (D) Volcano plot showing differential gene expression of LDA50-AIB1^LOW^ xenografts (*n* = 2) relative to control shRNA xenografts (*n* = 4). (E) PCR gene expression for *MMP2* and *FN1* in LDA50-AIB1^LOW^ xenografts (*n* = 2) relative to control shRNA xenografts. (F) Number of mice with confirmed pulmonary metastasis by H&E in the LDA50 group. (G) Representative images of H&E, KRT14, and E-cadherin IHC staining in lung tissues for HCC1806 AIB1^LOW^ and control shRNA. Mean ± SEM. Two-tailed t-test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Figure 5

Discussion {#s0045}
==========

Here, we show that the major portion of basal like TNBC cells depend on AIB1 expression for survival. However, cells that survive depletion of AIB1 by shRNA-mediated knockdown (AIB1^LOW^) or after chemotherapy treatment, can be maintained in serial passage with low-to-undetectable AIB1 mRNA expression. These AIB1^LOW^ cells are a distinct subpopulation that have reduced dependence on AIB1 signaling. The whole exome sequence analysis of the AIB1^LOW^ population identifies these cells as a subset of the bulk population that survives selection after AIB1 depletion. Furthermore, our data suggest that the presence of an AIB1^LOW^ cell gene expression signature in TNBC patient samples may be useful as a prognostic indicator of poor survival outcome following therapy, i.e., relative resistance to cytotoxic treatment. Thus AIB1^LOW^ cells could well be useful as a model to study therapeutic targeting of metastasis and for understanding chemotherapy resistance in TNBC.

Despite their increased proliferation and reduced sensitivity to chemotherapy in reduced serum conditions, HCC1806 AIB1^LOW^ cells did not show differences in classical CSC indicators *in vitro* or *in vivo*. Enrichment of CSC populations has been observed after chemotherapy treatment of TNBC [@bb0220] and CSC enrichment is hypothesized to contribute to resistance to treatment, disease recurrence, and metastasis [@bb0225]. Phenotypic markers to identify these rare populations continue to be an area of active research. However, the *in vivo* LDA results indicate that HCC1806 AIB1^LOW^ have different properties compared to control shRNA cells. Although, we cannot rule out the presence of CSC in the AIB1^LOW^ population, if present, they do not appear to influence the overall phenotype that we observe. The inability of AIB1^LOW^ cells to form tubes on Matrigel and their slower tumor growth and metastasis *in vivo* along with reduced adhesion gene expression and changes in inflammatory signaling suggest that cross talk of the HCC1806 AIB1^LOW^ cells with each other and/or their surrounding stroma environment is impeded, and this influences their tumorigenicity and metastasis potential.

The question then arises as to the downstream targets that play into differential AIB1 sensitivity in TNBC cells. Certainly, the regulation of adhesion and proteolytic genes, both *in vitro* and *in vivo,* is expected to influence the phenotype of AIB1^LOW^ TNBC cells and their interactions with components in the tumor microenvironment including fibroblasts, adipocytes, endothelial, bone marrow derived and immune cells. In addition, our findings show that type 2 inflammatory response genes are regulated by AIB1 expression and could contribute to tumorigenicity. Reduced AIB1 in TNBC cells activates the IFNɑ signaling pathway upregulates the angiostatic cytokine CXCL10 and this could contribute to the impaired tube formation phenotype of AIB1^LOW^ cell on Matrigel. It has been previously reported that CXCL10, and its cognate receptor CXCR3, have anti-angiogenic effects through the trafficking of immune cells or by activating endothelial cells; therefore, reducing vascular perfusion to sites of inflammation (reviewed in [@bb0335]). However, we did not observe significant differences in the vascularity of the tumors between groups suggesting that HCC1806 AIB1^LOW^ cells are not altering vascular mimicry or endothelial cell function.

The reduced tumorigenicity of HCC1806 AIB1^LOW^ cells *in vivo* became apparent only at low cell implant numbers suggesting that the pro-inflammatory effect exerted by too few tumor epithelial cells fails to overcome an anti-tumorigenic response from the stroma. Chemotherapy can reduce tumor size and our results show that a relatively indolent population of cells that survives chemotherapy have reduced levels of AIB1 protein indicative of tumor cells with the potential for recurrence or metastasis should cell density increase above a threshold. Thus, the AIB1^LOW^ cells have some of the hallmarks of dormant cells although gene expression comparisons of AIB1^LOW^ *versus* control shRNA cells on Matrigel™ did not show major changes in known dormancy gene signatures [@bb0340], [@bb0345].

The differences in the activated transcriptional pathways in HCC1806 AIB1^LOW^ cells compared to control cells suggests that there may be significant differences in the engagement of this nuclear coactivator at the chromatin level. AIB1 is known to interact with multiple nuclear receptors and other transcription factors [@bb0155] and AIB1 genomic engagement is altered in different breast cancer cell types and under different conditions. We conjecture that patterns of epigenetic modifications could determine whether AIB1 is activating pro-survival gene pathways in a subset of parental cell lines, whereas in AIB1^LOW^ cells these pathways are no longer controlled by the endogenous AIB1. In this regard it would be also interesting to compare the epigenetic profiles of the parental *vs* AIB1^LOW^ cells and compare the pattern of chromatin engagement of AIB1. The fact that an AIB1^LOW^ expression signature is correlated with worse outcome suggests that for future studies it will be important to determine the sensitivity of AIB1^LOW^ cells to other therapies and to design robust gene expression signatures that can predict the presence of AIB1^LOW^ cells in TNBC subtypes.

Materials and Methods {#s0050}
=====================

Cell Lines and Reagents {#s0055}
-----------------------

HCC1806 cell lines were purchased from ATCC® (\#CRL-233, Manassas, VA, USA). MDA-MB-468 (\#HTB-132, ATCC), MDA-MB-157 (\#HTB-24, ATCC), and HEK293T (\#CRL-3216) cells were obtained from the Georgetown University (GU) Tissue Culture Share Resource (TCSR) in Lombardi Comprehensive Cancer Center (LCCC). HUVEC cell lines were purchased from Lonza (\#CC-2517A, Walkersville, MD, USA). Cell lines were authenticated using short tandem repeat (STR) analysis by the TCSR prior to use. Cell lines were maintained under sub-confluent conditions (70--80%) and media was replenished every three days. PDX-HCI010 grafts were obtained from Huntsman Cancer Center and expanded in immunocompromised mice as previously described [@bb0350]. Cell lines and PDX tissues were mycoplasma negative by RADIL-IMPACT testing results and throughout this project by TCSR periodic screening. For additional details of media recipes, cell culture and maintenance, see [Supplementary Materials and Methods](#ec0005){ref-type="supplementary-material"}.

AIB1 mRNA Interference {#s0060}
----------------------

RNAi targeting sequences in AIB1 exon 6 and exon 14 were described previously [@bb0255], [@bb0355]. Oligo nucleotides were purchased from Bioneer, Inc. (Alameda, CA, USA). Scramble (\#1864) [@bb0360] and AIB1 short-hairpin RNAs (shRNAs) were purchased from Addgene (Cambridge, MA, USA). AIB1 shRNAs and Scramble plasmids were inserted into pLKO.1 puro (\#8453; Addgene) lentiviral vectors [@bb0365]. For viral production and shRNA infection, see [Supplementary Material and Methods](#ec0005){ref-type="supplementary-material"}. Cell lines were transfected with 200 nmol/L of siRNAs diluted in RPMI-1640 or DMEM with Lipofectamine 2000 (\#11668027; Invitrogen, Carlsbad, CA, USA).

Cellular Phenotype {#s0065}
------------------

Cell proliferation, serum-free cell survival, viability assays, and cell trace assays were performed and analyzed as previously described [@bb0370], [@bb0375]. Indirect intracellular staining of AIB1 was performed using the Nuclear Factor Fixation and Permeabilization kit (\#422601; BioLegend, San Diego, USA) following manufacturer\'s recommendations. Briefly, 1×10^6^ cells/ml densities were fixed, permeabilized, then incubated with 1.2 μg/ml of anti-rabbit human AIB1 (\#2126; Cell Signaling Technology, Danvers, MA, USA) primary antibody in suspension for 30--60 minutes. Upon incubation cells were rinse then incubated with 2.5 μg/ml of secondary isotype-specific fluorescent antibody, AlexaFluor488 goat anti--rabbit (\#A11008; Invitrogen) for 30 minutes prior to submission for analysis. Samples were analyzed using the LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA, USA). Cells were labeled using the CellTrace Violet (CTV, \#C34557, Invitrogen) dye. Briefly, cells (1×10^6^) were incubated with 1--2 μM dye in 1 ml PBS for 20-minutes at 37 °C. Excess dye was rinsed off by adding 9 ml of serum-supplemented media, centrifuged at 1,000 rpm for 5-minutes, after removal of the supernatant the cell pellet was resuspended in fresh media. Resuspended cells (1×10^5^) were seeded in 60×15 mm dishes to monitor mitotic index for 3 or 5 days (T~3~, T~5~) after seeding. Cell lines were trypsinized, counted, and fixed in 1%PFA prior to flow cytometry analysis. An aliquot of unlabeled and labeled cells at time zero (T~0~) were used as reference for the highest signal of the dye. Tube formation assays on Matrigel™ (\#354230; BD Biosciences) and tumorsphere assays were conducted and analyzed as previously described [@bb0230], [@bb0295]. Separating cells from basement matrix was adapted from Lee and colleagues [@bb0280]. Briefly, media was removing from each well followed by a rinse with 200 μl of PBS per well. A volume of 200 μl of cold 5 mM EDTA-PBS was added to each well and the basement matrix with attached cells was scratched using a 1000 low-retention tip and transferred to a 15 ml conical tube. This was repeated for each well in each condition. The conical tube was then vortexed briefly and the volume of cold EDTA-PBS was doubled. The mix was incubated in ice for 5 minutes follow by a quick vortex prior to centrifugation at 1000 rpm at 4 °C for 10 minutes. Digestion of Matrigel required an approximate 1:10 ratio (i.e., 450 μl of EDTA-PBS to 50 μl of 100% Matrigel) at the time of incubation but this reference is dependent on the integrity of the Matrigel (length of culture and accumulation of proteases by cells) and the type of cells utilized. If Matrigel is not completely digested, removed the aqueous part and add 1:1 cold EDTA-PBS to the remaining polymerized Matrigel. Incubate in ice for 5 minutes, vortex briefly, then centrifuge. The resulting cell pellet was lysed for RNA or protein extraction. For additional details, see [Supplementary Material and Methods](#ec0005){ref-type="supplementary-material"}.

RNA Extraction and Gene Expression Analysis {#s0070}
-------------------------------------------

Gene expression of target genes was normalized (ΔCt) to the average expression of three housekeeping genes; *ACTB*, *B2M*, and *GAPDH*. Gene expression relative to control shRNA was calculated using 2^-ΔΔC^~T~, as previously described [@bb0380]. For the list of primers and their sequences, see [Supplementary Material and Methods](#ec0005){ref-type="supplementary-material"}. For genome-wide gene expression analysis, total RNA samples with RNA integrity number (RIN) \>8.0 were submitted to the UCLA Neuroscience Genomics Core (UNGC). The HumanHT-12 v4.0 Expression BeadChip (GRCh38/hg38) (Illumina, San Diego, CA, USA) covering more than 47,000 transcripts was utilized and direct hybridization was performed following manufacturer\'s recommendations. Average signal intensity was normalized and log-transformed using GenePattern v3.9.10 suite (Broad Institute of MIT and Harvard, Cambridge, MA, USA) as described previously [@bb0385]. Gene set enrichment analysis (GSEA) was carried out to identify common pathways affected by AIB1 silencing. For NanoString (Seattle, WA, USA) gene expression of HCC1806-BL2 AIB1^LOW^ (*n* = 2) and control shRNA (*n* = 4) xenografts, total RNA and protein were extracted from snap frozen xenograft tissues (LDA50 experimental group) following manufacturer\'s recommendations [@bb0390]. nCounter® PanCancer Progression Panel (XT-CSO-PROG1--12; NanoString Technologies) was acquired through the GU Genomics and Epigenomics Shared Resources (GESR) in LCCC. Samples were hybridized and processed using the nCounter® SPRINT Profiler. nSolver v4.0 software (NanoString Technologies) was used for data analysis and for the generation of expression tables.

Next Generation Sequencing (NGS) and Exome Sequencing {#s0075}
-----------------------------------------------------

Cells from two independent shRNA infections: control shRNA, shAIB1\#1, shAIB1\#2 (x2), were carried out for five passages. DNA was isolated using the DNeasy Blood&Tissue kit (Qiagen). Whole Exome sequencing was carried out by the UCLA Neuroscience Genomics Core. 65 Exome sequencing hybridized with probes from the Nimblegen SeqCap EZ Exome v2/3 Kapa/IVTL kit (Roche, Basel, Switzerland) and samples were run on an Illumina Hiseq4000 and an average of 61 million paired reads were acquired for each sample. Exome sequencing data were analyzed and mapped to HG38 using BWA [@bb0395] and the variant calling analysis was performed by Samtools and Bcftools [@bb0400], [@bb0405]. Reads were filtered by quality (QUAL \>20) and number of reads (DP \<100).

Protein Detection and Immuno-Blot (Western Blot) {#s0080}
------------------------------------------------

Total protein lysates were extracted from end-point cell cultures following a rinse with cold PBS or from snap frozen cell pellets stored briefly at −80 °C as previously described [@bb0355]. Antibodies expression were verified with manufacture\'s control cell lines. For list of antibodies and additional information, see [Supplementary Material and Methods](#ec0005){ref-type="supplementary-material"}.

Tumor Transplantation Experiments: Xenografts {#s0085}
---------------------------------------------

Experiments involving animals were approved by the GU-IACUC and were conducted according to the NIH guidelines for the care and use of laboratory animals. Immunocompromised 3-weeks old female mice were purchased from Envigo (Athymic Nude-Foxn1^nu^, \#6901F, Indianapolis, IN, USA) and from Jackson Laboratory (NSG (NOD.Cg-Prkdc^scid^ Il2rg^tm1Wjl^/SzJ), \#005557, Bar Harbor, ME, USA). A week after acclimation, female mice underwent bilateral removal of the endogenous epithelium from the inguinal mammary fat pad (MFP) prior to injection of tumor cells in Matrigel™ suspension (20 μl) or tumor fragments as described previously [@bb0245], [@bb0410], [@bb0415]. Orthotopic injections or tumor fragments into the cleared MFP were monitored three times a week. Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining were performed on 5-μm sections formalin-fixed, paraffin embedded (FFPE) tissue sections by GU Histopathology and Tissue Shared Resource (HTSR). Histopathology analysis was conducted by a board-certified pathologist at GU.

Statistics and Image Analysis {#s0090}
-----------------------------

Statistical differences and linear regression analysis were performed using the GraphPad Prism software v8.0 (Graph-Pad Software Inc., San Diego, CA, USA). Phenotypic and gene expression differences were measured by unpaired student t-Test, One-way and Two-way ANOVA as indicated. Non-linear regression determined results in viability assays and data from population-based registries. Median overall survival (OS) was calculated using Kaplan--Meier estimates and compared using log-rank tests. The significance of change reflects *P* \< .05, *P* \< .01, and *P* \< .001 and were considered statistically significant, unless stated otherwise. For information on image processing and analysis, see [Supplementary Material and Methods](#ec0005){ref-type="supplementary-material"}.

The following are the supplementary data related to this article.Supplementary Material and MethodsSupplementary Material and MethodsSupplementary Figure 1**Molecular characterization of AIB1 expressing TNBC cell lines following chemotherapy and RNAi treatment.** (A) Quantitation of band intensity normalized to Actin for listed proteins from Western blots in chemotherapy-treated surviving basal like subtypes of TNBC cell lines. (B) Intracellular AIB1 protein expression of parental HCC1806 and MDA-MB-468 cells analyzed by flow cytometry. (C) Schematic timeline for shRNA lentiviral infection and puromycin selection. Representative images of shRNA-treated TNBC cell lines after puromycin selection. (D) Schematic timeline for siRNA treatment of HCC1806 cell lines. (E) Proliferation of siRNA treated HCC1806 cells. (E) Representative Western blot image for AIB1 protein in siRNA-treated HCC1806 cells at 72 and 96 hours. Two-way ANOVA followed by Dunnett\'s multiple comparisons test in A. Linear regression (slope coefficient) in D. \*P ≤ 0.05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Supplementary Figure 1Supplementary Figure 2**Molecular characterization of serial passaged HCC1806 AIB1**^**LOW**^**cells *in vitro*.** (A) Representative Western blot images for AIB1 protein and PCR gene expression of *AIB1* in serial passaged HCC1806 AIB1^LOW^ relative to control shRNA. (B) Proliferation analysis by CellTrace Violet of serial passaged HCC1806 AIB1^LOW^ relative to control shRNA in 10% or 1% serum-supplemented growth media after 72 hours. (C) Heatmap showing differentially expressed genes in HCC1806 AIB1^LOW^ cells relative to control shRNA from cell lines (2D culture). (D) Quantification of genomic variant reads as percentage of total reads for each genomic locus in HCC1806 AIB1^LOW^ cells relative to control shRNA. TP53 intron 6 is shown as a control (*n* = 2). One-way and two-way ANOVA followed by Dunnett\'s multiple comparisons test in A (lower panel) and D, respectively. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Supplementary Figure 2Supplementary Figure 3Characterization of HCC1806 AIB1^LOW^ cells**.** (A) Quantification of adherent HCC1806 AIB1^LOW^ on plastic compared to control shRNA cells seeded at similar densities and measured over time. Adherent cells were counted per well (*n* = 6) following decanting of the supernatant after seeding and stained with Crystal Violet. (B) Adhesion properties of HCC1806 AIB1^LOW^ compared to control shRNA cells represented as cell index (left) measured by an electrical-cell impedance substrate array and the area under the curve (right). (C) Percentage of adhered HCC1806 AIB1^LOW^ compared to control shRNA cells 1-hour post seeding and normalized to percentage of adhered cells 24-hours post seeding**.** (D) Schematic describing tumorsphere culture embedded in Matrigel ^TM^. (E) Representative images of HCC1806 AIB1^LOW^ compared to control shRNA cells forming tumorspheres. (F) Correlation analysis for tumorsphere size and count from HCC1806 AIB1^LOW^ compared to control shRNA cells. (G) Schematic describing tumorsphere culture in suspension using ultra-low attachment plates. (H) Representative micrographs of serial passaged HCC1806 AIB1^LOW^ compared to control shRNA cells cultured in 1% serum-supplemented (top) and serum-free conditions (bottom). **(I)** Tumorsphere count using diameter (ᴓ) of the longest axis. (J) Tube-formation assay of parental HCC1806 treated with increasing concentrations of MCB613 and DMSO for 12-hours, trypsinized, then seeded onto Matrigel for 72-hours. (K) Western blot analysis of AIB1 protein after MCB613 treatment of HCC1806 cells cultured onto Matrigel after 72h. Graphs are representative of at least two independent experiments. Mean ±SEM. Scale bar = 1 mm (J). Two-tailed t-test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Supplementary Figure 3Supplementary Figure 4Gene expression analysis of HCC1806 AIB1^LOW^ cell lines on Matrigel. 4. (A) Venn Diagram showing overlap of leading-edge lists from inflammatory pathways in 4C. (B) Independent gene expression validation of down-regulated genes during tube-formation in HCC1806 control shRNA cells ([Figure 4](#f0020){ref-type="fig"}). Data analysis and normalization as described in Figure (C) Independent gene expression validation of upregulated genes during tube-formation in HCC1806-BL2 AIB1^LOW^ cells. Two biological samples from each condition were submitted for microarray analysis and each sample was validated. Graphs are representative of at least two independent experiments. Mean ±SEM. Two-tailed t-test. \**P* ≤ .05, \*\**P* ≤ .01, \*\*\**P* ≤ .001.Supplementary Figure 4Supplementary Figure 5Analysis of HCC1806AIB1^LOW^ orthotopic xenografts. (A) Average end-point tumor size and weight of 1×10^6^ HCC1806AIB1^LOW^ compared to control shRNA cells injected into the cleared mammary fat pad of 4-week old nude mice; *n* = 10. (B) Line graphs of HCC1806AIB1^LOW^ cells compared to control shRNA cells showing tumor development over time. **(**C) Representative images of H&E and IHC staining from primary tumor graft sections of the 1×10^6^ HCC1806 AIB1^LOW^ compared to control shRNA xenografts. (D)Quantification of stromal glycoprotein stained with periodic-acid shift (PAS) stromal collagen or (E) stained with Masson's trichome staining (MTS). (F) Representative H&E stains from LDA50-HCC1806AIB1^LOW^ versus control shRNA showing levels of tissue necrosis.Supplementary Figure 5Supplementary Figure 6Recurrence free survival (RFS) of chemotherapy treated patients with breast cancer relative to the AIB1^LOW^ 20 gene expression signature**.** (A) List of signature genes derived from a comparison of HCC1806 AIB1^LOW^ relative to control shRNA xenograft tumors. (B) Kaplan-Meier curve showing significantly longer RFS of patients which tumors lacking the AIB1^LOW^ 20 gene expression signature. Log-rank p values and hazard ratios (HRs; 95% CI) are shown. Note: For signature genes whose expression was downregulated in AIB1^LOW^ tumors the respective expression levels in breast cancer specimens were inverted for the combined analysis to take the directionality of expression of the signature genes into account.Supplementary Figure 6
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